Rigel Pharmaceuticals (RIGL) Set to Report Q4 FY2025 Earnings After the Bell — Here’s What to Expect
Ticker: RIGL | Exchange: NASDAQ | Report Date: March 3, 2026, after market close Rigel Pharmaceuticals, a specialty pharma company...
ADVERTISEMENT
Healthcare
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens
Zymeworks Inc. (NASDAQ: ZYME), a Canada-based clinical-stage biotechnology company, on Monday reported a wider net loss for the fourth quarter...
Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report
Smith+Nephew (NYSE: SNN) reported revenue growth across its operating segments for the fourth quarter of fiscal 2025. The medical technology...
Sleep Tech Demand Fuels ResMed
Executive Summary ResMed has transitioned from a cyclical medical device manufacturer into a structurally growing digital health platform anchored in...
BrightSpring Health Services Q4 FY25 earnings jump on strong revenue growth
BrightSpring Health Services, Inc. (NASDAQ: BTSG), a provider of home and community-based health services, on Friday reported a sharp increase...
Agilent Q1 Revenue Rises 7%, Net Income Declines
Agilent Technologies Reports Mixed 1Q 2026 Financial Results An analysis of recent data released via infographic on Agilent Technologies, Inc....
UnitedHealth Group Incorporated (UNH) Drops 5.8% — Developing Story
UnitedHealth Group Incorporated (UNH) Drops 5.8% — Developing Story
Important takeaways from Medtronic’s (MDT) Q3 2026 earnings report
Shares of Medtronic Plc (NYSE: MDT) declined this week, despite the company reporting stronger-than-expected Q3 2026 earnings. Investors were unsettled...
Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited
Shares of Pulse Biosciences Inc. (Nasdaq: PLSE) were down about 2% in afternoon trading on Thursday after the company reported...
Madrigal Pharmaceuticals, Inc. reports strong Rezdiffra sales growth in Q4 2025; first full year of launch approaches $1 billion in net sales
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported fourth-quarter 2025 results showing continued commercial uptake of its lead product Rezdiffra (resmetirom), with...